术前长期使用类固醇与慢性肢体威胁性缺血患者股腘及股-远端旁路术后死亡率和截肢率增加相关
基于ACS-NSQIP 2012至2021年数据,8,324例因慢性肢体威胁性缺血行股腘或股-远端旁路术的成人患者中,408例(4.9%)术前长期使用类固醇。风险校正分析显示,长期使用类固醇与30天死亡率(AOR 1.7,P=0.05)、截肢(AOR 2.05,P<0.001)、死亡和/或截肢复合结局(AOR 1.959,P<0.001)、未处理的原发通畅性丧失(AOR 2.31,P=0.002)、出血(AOR 1.33,P=0.011)及非计划重返手术室(AOR 1.36,P=0.014)显著相关。
要点
- 术前长期使用类固醇与30天死亡率(AOR 1.7)、截肢(AOR 2.05)及死亡/截肢复合结局(AOR 1.959)风险升高相关。
- 长期使用类固醇组未处理的原发通畅性丧失(AOR 2.31)、出血(AOR 1.33)和非计划重返手术室(AOR 1.36)风险亦显著升高。
- 在Rutherford V/VI级(组织缺损)患者中,长期使用类固醇与结局无显著差异,提示类固醇效应在晚期外周动脉疾病中可能较弱。
核心结论
- 在因慢性肢体威胁性缺血行股腘或股-远端旁路术的患者中,术前长期使用类固醇与30天死亡率、大截肢、再入院、出血、重返手术室及未处理的原发通畅性丧失风险升高相关。
- 在Rutherford V或VI级(组织缺损)患者中,长期使用类固醇与结局无显著差异,提示类固醇效应在晚期外周动脉疾病患者中可能较不明显。
- 这些发现可能有助于医生对接受长期类固醇治疗的患者进行风险分层和关于开放血运重建的术前讨论。
- 需要更多研究包括随机试验来指导该队列围手术期类固醇管理。
研究设计与样本
- 回顾性队列研究,使用美国外科医师学会国家手术质量改进计划(ACS-NSQIP)2012至2021年数据。
- 纳入所有因慢性肢体威胁性缺血行股腘或股-远端旁路术并使用单段自体静脉的成人患者。
- 按术前长期使用类固醇(Group I)与术前未使用(Group II)分层。
- 共纳入8,324例患者,Group I 408例(4.9%),Group II 7,916例(95.1%);66.8%为男性,33.2%为女性,中位年龄68岁。
主要发现
- Group I与Group II比较:女性比例42.2% vs 32.8%,慢性阻塞性肺疾病20.6% vs 11.8%,糖尿病45.9% vs 48%,吸烟30.6% vs 45.4%,ASA III或IV级98% vs 96.5%(均P<0.05)。
- 主要结局:30天死亡率Group I 3.3% vs Group II 1.7%,截肢率Group I 5.9% vs Group II 2.8%,30天死亡和/或截肢复合结局Group I 9.1% vs Group II 4.5%(均P<0.05)。
- 次要结局中具有统计学显著性的包括:未处理的原发通畅性丧失Group I 4.2% vs Group II 1.7%,显著出血Group I 26.2% vs Group II 16.5%,伤口感染/并发症Group I 18.6% vs Group II 15%,重返手术室Group I 21.8% vs Group II 16.7%(均P<0.05)。
- 风险校正分析:长期使用类固醇对30天死亡率(AOR 1.7,P=0.05)、截肢(AOR 2.05,P<0.001)、死亡和截肢复合结局(AOR 1.959,P<0.001)、未处理的原发通畅性丧失(AOR 2.31,P=0.002)、出血(AOR 1.33,P=0.011)及非计划重返手术室(AOR 1.36,P=0.014)有统计学显著影响。
- 与Rutherford V和VI级(组织缺损)患者相比,Group I中Rutherford IV级(静息痛)患者更可能发生30天死亡率、大截肢及死亡和截肢复合结局。
临床怎么用
- 作者认为,这些发现可能有助于医生对接受长期类固醇治疗的患者进行风险分层和关于开放血运重建的术前讨论。
- 作者指出,需要更多研究包括随机试验来指导该队列围手术期类固醇管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Steroids are a commonly prescribed medication in the United States and have been associated with poor surgical and treatment outcomes. The objective of this study is to assess the relationship between chronic steroid use and surgical outcomes of femoropopliteal and femoral-distal bypasses in patients suffering from chronic limb threatening ischemia (CLTI). METHODS: All adult patients undergoing femoropopliteal and femoral-distal bypasses with single segment autologous vein with an indication of CLTI in the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) between 2012 and 2021 were stratified between chronic preoperative steroid use (Group I) and no preoperative use (Group II). Primary outcomes of the study included 30-day mortality, amputation, and combined outcome of mortality and/or limb loss. Secondary outcomes included specific bypass related, cardiovascular, respiratory and renal outcomes. RESULTS: A total of 8,324 patients (66.8% Male, 33.2% Females) underwent peripheral arterial bypass operations for the indication of chronic limb threatening ischemia. The median age was 68 years. Group I included 408 patients (4.9%) and Group II included 7,916 patients (95.1%). As compared to patients in Group II, those in Group I were more likely to be females (Group I: 42.2% vs. Group II: 32.8%), more likely to have co-existing chronic obstructive pulmonary disease (Group I: 20.6% vs. Group II: 11.8%), less likely to be diabetic (Group I: 45.9% vs. Group II: 48%), less likely to be smokers (Group I: 30.6% vs. Group II: 45.4%) and more likely to be in American Society of Anesthesiologists III or IV Classes (Group I: 98% vs. Group II: 96.5%) (all P < 0.05). Primary outcomes were as follows: 30-day mortality (Group I: 3.3% vs. Group II: 1.7%), amputation (Group I: 5.9% vs. Group II: 2.8%), 30-day mortality and/or amputation (Group I: 9.1% vs. Group II: 4.5%) (all P < 0.05). Among secondary outcomes, the following were found to be statistically significant: untreated loss of patency (Group I: 4.2% vs. Group II: 1.7%), significant bleeding (Group I: 26.2% vs. Group II: 16.5%), wound infection/complication (Group I: 18.6% vs. Group II: 15%), and return to operating room (Group I: 21.8% vs. Group II: 16.7%) (all P < 0.05). As compared to patients with an indication of tissue loss (Rutherford's class V and VI), patients in Group I with an indication of rest pain (Rutherford's class IV) were more likely to experience 30-day mortality, major amputation and a composite of mortality and amputation. Risk adjusted analysis showed that chronic steroid use has a statistically significant effect on 30-day mortality (adjusted odds ratio [AOR] 1.7, P = 0.05), amputation (AOR 2.05, P < 0.001), composite outcomes of mortality and amputation (AOR 1.959, P < 0.001), untreated loss of patency (AOR 2.31, P = 0.002), bleeding (AOR 1.33, P < 0.011) and unplanned return to the operating room (AOR 1.36, P = 0.014). CONCLUSIONS: Chronic steroid use in patients undergoing femoropopliteal or femoral-distal bypass is associated with a higher risk of 30-day mortality, major amputation, readmission, bleeding, return to operating room, and untreated loss of patency. No significant difference in outcomes were appreciated in patients with chronic steroid use and with Rutherford class V or VI disease (tissue loss), suggesting that the effects of steroids may be less prominent in those with the most advanced peripheral arterial disease. These findings may aid physicians with risk stratification and preoperative discussions regarding open revascularization in patients receiving chronic steroid therapy. More studies including randomized trials are needed to guide perioperative management of steroids in this cohort.
引用
- Dogbe L, Zil-E-Ali A, Krause KJ, et al. Preoperative Chronic Steroid Use is Associated with Increased Incidence of Postoperative Mortality and Limb Loss following Peripheral Arterial Bypass Surgery for Chronic Limb Threatening Ischemia. Ann Vasc Surg. 2023. PMID: 38154493. doi:10.1016/j.avsg.2023.11.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。